Enliven Therapeutics updated early phase I results for ELVN-001 in chronic myeloid leukemia (CML), with the company’s proposed go-forward 80-mg cohort showing major molecular response increasing to 48% versus 38% previously reported at 24 weeks. Coverage attributed the updated performance to discussion at hematology conferences and analyst expectations. ELVN-001 is a small-molecule kinase inhibitor designed to target BCR::ABL1, the oncogenic driver in CML. The program is positioned for next-stage development, with a phase III trial expected to start in the second half of the year. For investors and competitors, the update matters because ELVN-001 aims to deepen response rates in previously treated patients—an area where incremental gains in molecular response can influence future combination and line-of-therapy positioning.